Associations of HSP90AA2 gene polymorphisms with disease susceptibility, glucocorticoids efficacy and health-related quality of life in Chinese systemic lupus erythematosus patients

다국어 초록 (Multilingual Abstract)

Although the current glucocorticoids (GCs) treatment for systemic lupus erythematosus (SLE) is effective to a certain extent, the difference in therapeutic effect between patients is still a widespread problem. Some patients can have repeated attacks that greatly diminish their quality of life. This study was conducted to investigate the relationship between HSP90AA2 polymorphisms and disease susceptibility, GCs efficacy and health-related quality of life (HRQoL) in Chinese SLE patients. A case–control study was performed in 470 SLE patients and 470 normal controls. Then, 444 patients in the case group were followed up for 12 weeks to observe efficacy of GCs and improvement of HRQoL. Two single nucleotide polymorphisms (SNPs) of HSP90AA2 were selected for genotyping: rs1826330 and rs6484340. HRQoL was assessed using the SF-36 questionnaire.
The minor T allele of rs1826330 and the TT haplotype formed by rs1826330 and rs6484340 showed associations with decreased SLE risk (T allele: PBH = 0.022; TT haplotype: PBH = 0.033). A significant association between rs6484340 and improvement of HRQoL was revealed in the follow-up study. Five subscales of SF-36 were appeared to be influenced by rs6484340: total score of SF-36 (additive model: PBH = 0.026), physical function (additive model: PBH = 0.026), rolephysical (recessive model: PBH = 0.041), mental health (dominant model: PBH = 0.047), and physical component summary (additive model: PBH = 0.026). No statistical significance was found between HSP90AA2 gene polymorphisms and GCs efficacy. These results revealed a genetic association between HSP90AA2 and SLE. Remarkably, HSP90AA2 has an impact on the improvement of HRQoL in Chinese population with SLE.

참고문헌 (Reference)

1 Tissing WJ, "mRNA expression levels of (co)chaperone molecules of the glucocorticoid receptor are not involved in glucocorticoid resistance in pediatric ALL" 19 : 727-733, 2005

2 Hochberg MC, "Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus" 40 : 1725-, 1997

3 Deng Y, "Updates in lupus genetics" 19 : 68-, 2017

4 Lau CS, "The socioeconomic burden of SLE" 5 : 400-404, 2009

5 Bazso A, "The importance of glucocorticoid receptors in systemic lupus erythaematosus: a systematic review" 14 : 349-351, 2015

6 Gabryel M, "The impact of genetic factors on response to glucocorticoids therapy in IBD" 51 : 654-665, 2016

7 Carter EE, "The global burden of SLE: prevalence, health disparities and socioeconomic impact" 12 : 605-620, 2016

8 Lee SY, "The correlation between plasma brain-derived neurotrophic factor and cognitive function in bipolar disorder is modulated by the BDNF Val66Met polymorphism" 6 : 37950-, 2016

9 Azeredo LA, "The brain-derived neurotrophic factor (BDNF) gene Val66Met polymorphism affects memory performance in older adults" 39 : 90-94, 2017

10 Tsokos GC, "Systemic lupus erythematosus" 365 : 2110-2121, 2011

11 Zou YF, "Single nucleotide polymorphisms of HSP90AA1 gene influence response of SLE patients to glucocorticoids treatment" 5 : 222-, 2016

12 Shukla HD, "Role of hsp90 in systemic lupus erythematosus and its clinical relevance" 2012 : 728605-, 2012

13 Ruiz-Arruza I, "Restrictive use of oral glucocorticoids in systemic lupus erythematosus and prevention of damage without worsening long-term disease control: an observational study" 70 : 582-591, 2018

14 Ouyang J, "Nuclear HSP90 regulates the glucocorticoid responsiveness of PBMCs in patients with idiopathic nephrotic syndrome" 14 : 334-340, 2012

15 Monahan RC, "Neuropsychiatric symptoms in systemic lupus erythematosus: impact on quality of life" 26 : 1252-1259, 2017

16 Li X, "Negative relationship between expression of glucocorticoid receptor alpha and disease activity: glucocorticoid treatment of patients with systemic lupus erythematosus" 37 : 316-321, 2010

17 Hanly JG, "Mood disorders in systemic lupus erythematosus: results from an international inception cohort study" 67 : 1837-1847, 2015

18 Kahlenberg JM, "Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus" 64 : 249-263, 2013

19 Koh MJ, "Influence of the BDNF Val66Met polymorphism on coping response to stress in patients with advanced gastric cancer" 77 : 76-80, 2014

20 Zou YF, "Impact of environmental factors on efficacy of glucocorticoids in chinese population with systemic lupus erythematosus" 36 : 1424-1430, 2013

21 Romeis JC, "Heritability of SF-36 among middle-age, middle-class, male-male twins" 43 : 1147-1154, 2005

22 Tukaj S, "Heat shock protein 90: a pathophysiological factor and novel treatment target in autoimmune bullous skin diseases" 24 : 567-571, 2015

23 Kwak Y, "Health-related quality of life and mental health of elderly by occupational status" 46 : 1028-1037, 2017

24 Kirschke E, "Glucocorticoid receptor function regulated by coordinated action of the Hsp90 and Hsp70 chaperone cycles" 157 : 1685-1697, 2014

25 Qiao B, "Genomewide gene-based analysis of rheumatoid arthritis-associated interaction with PTPN22 and HLA-DRB1" 3 (3): S132-, 2009

26 Perez-Hernandez J, "Extracellular vesicles as therapeutic agents in systemic lupus erythematosus" 18 : E717-, 2017

27 Lauten M, "Expression of heat-shock protein 90 in glucocorticoid- sensitive and -resistant childhood acute lymphoblastic leukaemia" 17 : 1551-1556, 2003

28 Ripley BJ, "Elevated levels of the 90 kDa heat shock protein (hsp90) in SLE correlate with levels of IL-6 and autoantibodies to hsp90" 17 : 341-346, 2001

29 Moritani T, "Effect of exericse and nutrition upon lifestyle-related disease and cognitive function" 61 (61): S122-S124, 2015

30 Wu Y, "Depression induces poor prognosis associates with the down-regulation brain derived neurotrophic factor of serum in advanced small cell lung cancer" 7 : 85975-85986, 2016

31 Zhang S, "Chinese SLE Treatment and Research group (CSTAR) registry: V. gender impact on Chinese patients with systemic lupus erythematosus" 24 : 1267-1275, 2015

32 Zou YF, "Association study of glucocorticoid receptor genetic polymorphisms with efficacy of glucocorticoids in systemic lupus erythematosus: a prospective cohort study" 46 : 531-536, 2013

33 Mok CC, "Association of depressive/anxiety symptoms with quality of life and work ability in patients with systemic lupus erythematosus" 34 : 389-395, 2016

34 Zou YF, "Association of BDNF Val66Met polymorphism with both baseline HRQOL scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine" 25 : 145-152, 2010

35 Valassi E, "Affective alterations in patients with Cushing's syndrome in remission are associated with decreased BDNF and cortisone levels" 176 : 221-231, 2017